This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: We appreciate clarification by the investigators that they, rather than the sponsors, initiated the ENHANCE study. It is also clear that they considered this relatively small-scale surrogate end point study to be an important next step in the evaluation of ezetimibe when used in combination with simvastatin. Nonetheless, we continue to question the scientific value of the ENHANCE study given its completion well after drug approval.

As noted in another JAMA Commentary concerning the ENHANCE study,¹ measures of subclinical atherosclerosis such as carotid IMT are more proximate than lipid levels to measures of health benefits such as cardiovascular events, but wall thickness is not the only determinant of cardiovascular events risk. Medication effects on IMT and clinical events could differ.¹

Surrogate end point data can be of critical scientific importance early in the drug development process to hasten drug approval.² But we remain unconvinced of the scientific value . . . [Full Text of this Article]

Philip Greenland, MD; Donald Lloyd-Jones, MD, ScM
Department of Preventive Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Critical Lessons From the ENHANCE Trial
Philip Greenland and Donald Lloyd-Jones
JAMA. 2008;299(8):953-955.
EXTRACT | FULL TEXT  

RELATED LETTER

The ENHANCE Study and Marketing Ezetimibe
Fatima Akdim, John J. P. Kastelein, and Daniel Gaudet
JAMA. 2008;299(23):2747.
EXTRACT | FULL TEXT